James Bornheimer has been named chief financial officer of CardioOptics (Boulder, Colorado). Bornheimer previously was an executive with Pfizer's Hospital Products Group. CardioOptics is the developer of the Trans-Blood Vision system, which uses infrared illumination to create real-time video images of the interior structures of vessels and anatomical structures where blood is present.

John Erb has been named chief executive officer of CHF Solutions (New York). Most recently, Erb was president, chief executive officer and director of IntraTherapeutics. CHF Solutions has developed a mechanical pump/filter system to remove excess fluid in congestive heart failure patients, as an alternative to drug therapies and is seeking 510(k) clearance for the device.

Richard Vance, MD, has been named chief executive officer of CorSolutions Medical (Buffalo Grove, Illinois). He replaces Peter Smith, who has resigned as chairman and CEO, for personal reasons, but will assist the company in the transition period. Vance has served as CorSolutions' president and chief operating officer since July 2001. He joined the company in August 2000 as chief medical officer. CorSolutions develops health intelligence and offers population-based chronic care management for individuals affected by chronic diseases, including coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, diabetes and asthma.

David Lentz, PhD, has joined CryoCor (San Diego, California) in the newly created position of vice president, research and development. He will have responsibility for overseeing development of the CryoCor Cardiac Cryoablation System, which uses intracardiac cryoenergy to treat patients with irregular heart rhythms, including atrial fibrillation, as well as developing other technologies for the treatment of cardiac disease. Lentz has spent more than 25 years with various companies, including service as vice president and general manager of Medtronic''s Coronary Interventional Vascular business.

Jeffrey Mirviss has been named vice president of marketing at HeartStent (Minneapolis, Minnesota). Most recently, Mirviss was director of marketing at Boston Scientific. HeartStent is an emerging medical device company developing minimally invasive products and procedures to treat coronary artery disease.

Ronald Watkins has been named to the newly created position of vice president of quality and regulatory affairs for Rubicon Medical (Salt Lake City, Utah). Previously, Watkins was vice president of operations at National Laser. Rubicon manufactures interventional vascular medical devices and products.